Chemoswed has over the last several years collaborated with Oncopeptides in the discovery, development, scale-up and validation of a safe and efficient manufacturing method for melflufen hydrochloride, the active substance in Ygalo®.

Researchers at Chemoswed have contributed a new synthetic route which avoids some challenges associated with the highly potent compound. Downstream processing of melflufen still involves the application of certain specialised equipment ensuring adequate containment.

“We are pleased to announce that the first patient in our pivotal phase III study OCEAN has been dosed. This is a milestone for Ygalo® and for us as a company, and takes us one step closer to making Ygalo® available for late-stage multiple myeloma patients.” said Jakob Lindberg, CEO of Oncopeptides.

Dr Fredrik Lehmann, Head of CMC at Oncopeptides, said “our collaboration with Chemoswed has been very successful, delivering robust proprietary methodology for melflufen hydrochloride manufacturing. The team at Chemoswed has been highly dedicated and forthcoming throughout our endeavour”.